Skip to content

NCEL

NewCelX Ltd.

NASDAQ · Healthcare · Biotechnology · CH

$3.15
−6.80%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
+8.8%
EBIT
-34.2%
EPS
+67.4%
Free cash flow
+51.4%
Operating cash flow
+51.4%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
EBITDA
+38.4%
EBIT
+43.5%
Net income
EPS
+91.8%
Free cash flow
+35.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026